Expression of magnesium transporter genes in head and neck cancer patients underwent neoadjuvant cisplatin-based chemotherapy.
We aimed to investigate expression of magnesium transporter genes in patients with head and neck cancer who underwent cisplatin-based neoadjuvant chemotherapy and their association with serum magnesium level. Head and neck cancer patients scheduled to undergo neoadjuvant cisplatin-based chemotherapy were eligible for enrollment. Blood samples were obtained at three time points: prior to, during, and after completion of chemotherapy. Expression levels of magnesium transporter genes were determined by quantitative real-time PCR. A total of 23 patients were included in the final analysis. The average serum magnesium levels dropped 6.98 and 5.20% during and after completion of chemotherapy. There were neither significant associations between serum magnesium level and demographic variables nor tumor-related variables. SLC41A1 expression level was positively correlated with serum magnesium whereas TRPM6 expression level was negatively correlated with serum magnesium. Serum magnesium level decreased during cisplatin-based chemotherapy in head and neck cancer patients. Further studies are warranted to investigate optimal magnesium measurement and substitution protocol.
Department of Otolaryngology, Taichung Veterans General Hospital, No. 1650, Sec 4, Taiwan Boulevard, Taichung, Taiwan.
Yu-Jung
YJ
Lin
Fu-Chou
FC
Cheng
Li-Sheng
LS
Chien
Jin-Ching
JC
Lin
Rong-San
RS
Jiang
Shih-An
SA
Liu
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000494:pharmacology; D027682:Cation Transport Proteins / Q000378:metabolism*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D016903:Drug Monitoring / Q000379:methods; D020869:Gene Expression Profiling; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008274:Magnesium / Q000097:blood; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000009:adverse effects / Q000379:methods; D009367:Neoplasm Staging; D050053:TRPM Cation Channels / Q000378:metabolism*; D014883:Water-Electrolyte Imbalance / Q000097:blood / Q000139:chemically induced / Q000503:physiopathology
D000970:Antineoplastic Agents; D027682:Cation Transport Proteins; C476304:SLC41A1 protein, human; D050053:TRPM Cation Channels; C459082:TRPM6 protein, human; D008274:Magnesium; D002945:Cisplatin